美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

三倍做多標普生物-Direxion

163.19

-7.5500-4.42%

盤後：162.85-0.3400-0.21%19:59 EST

成交量：80.08萬

成交額：1.29億

市值：5.59億

市盈率：- -

高：166.00

開：164.08

低：155.50

收：170.74

52周最高：198.18

52周最低：32.55

股本：342.45萬

流通股本：342.45萬

量比：1.87

換手率：23.38%

股息：1.35

股息率：0.82%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Purple Biotech Ltd盤中異動股價大跌5.31%

美國OTC市場Nkgen Biotech, Inc.盤中異動股價大跌14.29%

美國醫療保險優勢計劃增長再度放緩

环球市场播报

Pharmacyte Biotech, Inc.盤中異動早盤股價大漲5.02%報0.684美元

和諧健康保險泰州中支被罰69萬，副總被罰15萬

大興機場臨空區，國際生物醫藥園（二期）衝出正負零

創業慧康新註冊《創業醫療健康數據匯聚系統軟件V6》等2個項目的軟件著作權

2026年中國生物科技授權交易將迎爆發式增長，有望創歷史新高

环球市场播报

長春高新：公司聚焦生物醫藥主業、深化創新驅動

今年已有30家醫藥企業擬赴港上市

四方光電：2026年1月，公司以自有資金受讓出資額並增資的方式取得蘇州暢合生物科技有限公司57.14%的股權

蘭溪即將通高鐵！金建高鐵蘭溪到建德段於2月14日開通

AMN醫療保健服務公司盤中異動臨近收盤大幅下挫5.03%報19.34美元

Humana公布季度虧損擴大，預計2026年盈利將下降

环球市场播报

Healthcare Services第四季度EPS為0.44美元高於預期

和諧健康保險泰安中支被罰16萬，涉編制虛假資料

醫療保健板塊動態：市場快訊解讀

百龍創園(605016.SH)擬設立百龍創園(南京)生物科技有限公司

AMN醫療保健服務公司盤中異動下午盤股價大漲5.27%

資本市場堅定看好「上海藥」！這張「成績單」見證申城創新實力

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/LABU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多標普生物-Direxion","latestPrice":163.19,"timestamp":1771621200000,"preClose":170.74,"halted":0,"volume":800769,"hourTrading":{"tag":"盘后","latestPrice":162.85,"preClose":163.19,"latestTime":"19:59 EST","volume":3668,"amount":596014.0281,"timestamp":1771635571728,"change":-0.34,"changeRate":-0.002083,"amplitude":0.007292},"delay":0,"changeRate":-0.04421928077779086,"floatShares":3424486,"shares":3424486,"eps":0,"marketStatus":"休市中","change":-7.55,"latestTime":"02-20 16:00:00 EST","open":164.08,"high":166,"low":155.5,"amount":129399922.22433001,"amplitude":0.061497,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":170.74,"sharesOutstanding":3424486,"nav":170.892,"aum":585215738.86,"dividendRate":0.008245,"bidAskSpread":0.002062,"preHourTrading":{"tag":"盘前","latestPrice":164.14,"preClose":170.74,"latestTime":"09:29 EST","volume":1897,"amount":312469.72351,"timestamp":1771597790012,"change":-6.6,"changeRate":-0.038655,"amplitude":0.031178},"postHourTrading":{"tag":"盘后","latestPrice":162.85,"preClose":163.19,"latestTime":"19:59 EST","volume":3668,"amount":596014.0281,"timestamp":1771635571728,"change":-0.34,"changeRate":-0.002083,"amplitude":0.007292},"volumeRatio":1.8710791898170518,"impliedVol":0.9405,"impliedVolPercentile":0.6853},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":3424486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.8710791898170518,"shares":3424486,"dividePrice":1.3455,"high":166,"amplitude":0.061497,"preClose":170.74,"low":155.5,"week52Low":32.55,"pbRate":"--","week52High":198.18,"institutionHeld":0,"latestPrice":163.19,"eps":0,"divideRate":0.008245,"volume":800769,"delay":0,"ttmEps":0,"open":164.08,"prevYearClose":159.39,"prevWeekClose":156.45,"prevMonthClose":165.86,"prevQuarterClose":159.39,"fiveDayClose":157.48,"twentyDayClose":195.95,"sixtyDayClose":142.38},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613297648","title":"Purple Biotech Ltd盤中異動 股價大跌5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613297648","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613297648?lang=zh_tw&edition=fundamental","pubTime":"2026-02-21 01:37","pubTimestamp":1771609027,"startTime":"0","endTime":"0","summary":"北京时间2026年02月21日01时37分，Purple Biotech Ltd股票出现异动，股价快速跳水5.31%。截至发稿，该股报0.523美元/股，成交量4.0033万股，换手率0.44%，振幅7.07%。Purple Biotech Ltd股票所在的生物技术行业中，整体跌幅为0.08%。Purple Biotech Ltd公司简介：Purple Biotech Ltd 是一家临床阶段公司，专注于推进一流疗法以克服肿瘤免疫逃避和耐药性，并为癌症患者创造治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022101370797a696a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022101370797a696a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LABU","BK4588","BK4007","PPBT","BK4585"],"gpt_icon":0},{"id":"2612234896","title":"美國OTC市場Nkgen Biotech, Inc.盤中異動 股價大跌14.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612234896","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612234896?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 04:34","pubTimestamp":1771533240,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日04时34分，美国OTC市场Nkgen Biotech, Inc.股票出现异动，股价急速下挫14.29%。美国OTC市场Nkgen Biotech, Inc.股票所在的生物技术行业中，整体跌幅为0.37%。美国OTC市场Nkgen Biotech, Inc.公司简介：NKGen Biotech Inc 是一家生物技术公司，开发基于活化 NK 细胞的神经退行性和肿瘤疾病细胞疗法。SNK 细胞可以大量生产并冷冻保存，同时保持高水平的细胞毒性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220043400a4b4419e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220043400a4b4419e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LABU","BK4585","BK4139","NKGN"],"gpt_icon":0},{"id":"2612688286","title":"美國醫療保險優勢計劃增長再度放緩","url":"https://stock-news.laohu8.com/highlight/detail?id=2612688286","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612688286?lang=zh_tw&edition=fundamental","pubTime":"2026-02-19 23:20","pubTimestamp":1771514400,"startTime":"0","endTime":"0","summary":"美国医疗保险优势计划参保人数同比增长放缓至约3%，在定价和医疗成本压力下，休曼纳（Humana）增加了会员，而联合健康集团和CVS Health旗下的安泰则流失了参保人。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-19/doc-inhnkpth0848747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XLV","LABU","XBI","BK4585","BK4588","BK4581"],"gpt_icon":0},{"id":"2612425413","title":"Pharmacyte  Biotech, Inc.盤中異動 早盤股價大漲5.02%報0.684美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612425413","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612425413?lang=zh_tw&edition=fundamental","pubTime":"2026-02-19 00:06","pubTimestamp":1771430793,"startTime":"0","endTime":"0","summary":"北京时间2026年02月19日00时06分，Pharmacyte  Biotech, Inc.股票出现波动，股价快速拉升5.02%。截至发稿，该股报0.684美元/股，成交量2.9323万股，换手率0.29%，振幅4.05%。Pharmacyte  Biotech, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Pharmacyte  Biotech, Inc.公司简介：PharmaCyte Biotech Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219000633a707a8fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219000633a707a8fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LABU","BK4585","PMCB","BK4588","BK4139"],"gpt_icon":0},{"id":"2611101921","title":"和諧健康保險泰州中支被罰69萬，副總被罰15萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2611101921","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611101921?lang=zh_tw&edition=fundamental","pubTime":"2026-02-14 23:03","pubTimestamp":1771081408,"startTime":"0","endTime":"0","summary":"蓝鲸新闻2月14日讯，近日，国家金融监督管理总局泰州监管分局发布了罚单，剑指和谐健康保险股份有限公司泰州中心支公司及其相关责任人。罚单显示，和谐健康保险股份有限公司泰州中心支公司的主要违法违规事实（案由）为：业务数据不真实、承诺给予或给予客户保险合同约定以外利益、财务数据不真实。针对上述违法违规行为，国家金融监督管理总局泰州监管分局对其罚款69万元；对和谐健康保险股份有限公司泰州中心支公司副总经理王擎警告并处罚款15万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1771068889721567457","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4581","BK4585","XBI","LABU","XLV","BK4588"],"gpt_icon":0},{"id":"2611118298","title":"大興機場臨空區，國際生物醫藥園（二期）衝出正負零","url":"https://stock-news.laohu8.com/highlight/detail?id=2611118298","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611118298?lang=zh_tw&edition=fundamental","pubTime":"2026-02-14 12:39","pubTimestamp":1771043940,"startTime":"0","endTime":"0","summary":"新京报讯 据“这里是大兴”微信公众号消息，大兴机场综保区内，随着最后一方混凝土浇筑完成，国际生物医药园 项目顺利冲出正负零建设节点，迈入主体结构施工新阶段。作为临空区投运的首个生物医药标厂项目，综保区国际生物医药园（一期）自2023年投入运营以来，凭借综保区特有的保税研发、保税生产等政策优势，已初步形成产业集聚。","market":"sh","thumbnail":"https://media.bjnews.com.cn/cover/2026/02/14/5686710861528375996.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/02/14/5686710861528375996.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1771041749129846.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1771041749129846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["161726","BK4588","LABU","BK4585","399441"],"gpt_icon":0},{"id":"2611192456","title":"創業慧康新註冊《創業醫療健康數據匯聚系統軟件V6》等2個項目的軟件著作權","url":"https://stock-news.laohu8.com/highlight/detail?id=2611192456","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611192456?lang=zh_tw&edition=fundamental","pubTime":"2026-02-14 09:34","pubTimestamp":1771032850,"startTime":"0","endTime":"0","summary":"证券之星消息，近日创业慧康新注册了2个项目的软件著作权，包括《创业医疗健康数据汇聚系统软件V6》、《创业医疗健康数据模型管理系统软件V6》等。今年以来创业慧康新注册软件著作权6个，较去年同期增加了20%。通过天眼查大数据分析，创业慧康科技股份有限公司共对外投资了61家企业，参与招投标项目8200次；财产线索方面有商标信息65条，专利信息123条，著作权信息780条；此外企业还拥有行政许可74个。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260214/32018863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0114","159760","XBI","VGT","161022","BK4588","LU0405327148.USD","300451","BK4585","BK0146","LABU","BK4581","XLV","LU0405327494.USD","BK0231"],"gpt_icon":0},{"id":"2611130059","title":"2026年中國生物科技授權交易將迎爆發式增長，有望創歷史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2611130059","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611130059?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 17:52","pubTimestamp":1770976320,"startTime":"0","endTime":"0","summary":"全球制药企业在专利到期前纷纷削减成本，正加大力度寻找中国研发的创新候选药物，行业分析师预计，今年相关授权交易规模将飙升至历史新高。　　中国大陆是这一浪潮的绝对核心。　　“未来 18–24 个月，这类对外授权交易总额有望再翻一番。全球药企正高度聚焦在中国寻找下一代创新药管线，并探索多种交易结构。”　　2026 年至今已宣布38 笔对外授权交易；2025 年全年为186 笔。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-13/doc-inhmskfk5919270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159837","LABU","BK4588","BK4585"],"gpt_icon":0},{"id":"2611295134","title":"長春高新：公司聚焦生物醫藥主業、深化創新驅動","url":"https://stock-news.laohu8.com/highlight/detail?id=2611295134","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611295134?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 16:35","pubTimestamp":1770971708,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)02月13日在投资者关系平台上答复投资者关心的问题。投资者提问：作为拿地最多的医药集团,建议公司加大拿地力度。医药只是赚点钱，多拿地才能造福社会,才能帮扶地方政府化解债务。长春高新回复：感谢关注，公司聚焦生物医药主业、深化创新驱动，努力提升公司核心竞争力，谢谢！为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260213/32017446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0075","BK0046","LABU","000661","399441","BK0239","BK4585","BK4588","BK0057","BK0028","BK0188","161726"],"gpt_icon":0},{"id":"2611990950","title":"今年已有30家醫藥企業擬赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2611990950","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611990950?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 00:17","pubTimestamp":1770913020,"startTime":"0","endTime":"0","summary":"据北京商报记者不完全统计，今年开年40余日，已有约30家医药企业递表港交所。　　药企扎堆赴港，“创新”成为关键词。上述30家企业中，13家为带有特殊标识“B”的未盈利的创新药、创新医疗器械企业。此外，还有信立泰、海特生物两股已于年内官宣正在筹划赴港上市。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-13/doc-inhmqrvv9450966.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","06978","BK1574","BK4585","09939","BK1515","SINA","BK1161","HEXmain","LABU"],"gpt_icon":0},{"id":"2610692400","title":"四方光電：2026年1月，公司以自有資金受讓出資額並增資的方式取得蘇州暢合生物科技有限公司57.14%的股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2610692400","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610692400?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 21:38","pubTimestamp":1770903480,"startTime":"0","endTime":"0","summary":"证券日报网2月12日讯 ，四方光电在接受调研者提问时表示，2026年1月，公司以自有资金受让出资额并增资的方式取得苏州畅合生物科技有限公司57.14%的股权。本次投资是基于公司战略发展规划所作出的审慎决策，旨在拓展公司在生物安全监测领域的业务布局。此次战略整合畅合生物，双方将在产品技术开发、运营生产和销售渠道等方面深度融合，将四方光电的传感器产业领域向更加高端的生物安全检测仪器领域拓展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-12/doc-inhmqmpz6698250.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-12/doc-inhmqmpz6698250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159837","LABU","BK0214","688665","BK4585","BK4588"],"gpt_icon":0},{"id":"2610254921","title":"蘭溪即將通高鐵！金建高鐵蘭溪到建德段於2月14日開通","url":"https://stock-news.laohu8.com/highlight/detail?id=2610254921","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610254921?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 21:37","pubTimestamp":1770903420,"startTime":"0","endTime":"0","summary":"来自铁路方面的最新消息，金建高铁兰溪到建德段将于2月14日开通，浙中水路汇聚、钱塘江中游枢纽兰溪市将开通高铁了。金建高铁实行分段建设，此次开通的为兰溪至建德段，兰溪至金华段需待在建的金华铁路枢纽扩容改造工程完工后，再引入枢纽、开通运营。《兰溪即将通高铁！金建高铁兰溪到建德段于2月14日开通》栏目主编：陈抒怡 文字编辑：陈抒怡 来源：作者：江南","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-12/doc-inhmqmqc3795903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","LABU","BK4585"],"gpt_icon":0},{"id":"2610946007","title":"AMN醫療保健服務公司盤中異動 臨近收盤大幅下挫5.03%報19.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610946007","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610946007?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 04:39","pubTimestamp":1770842399,"startTime":"0","endTime":"0","summary":"北京时间2026年02月12日04时39分，AMN医疗保健服务公司股票出现波动，股价快速跳水5.03%。截至发稿，该股报19.34美元/股，成交量66.875万股，换手率1.74%，振幅5.88%。AMN医疗保健服务公司股票所在的医疗设施行业中，整体涨幅为5.58%。AMN医疗保健服务公司公司简介：AMN Healthcare Services Inc 在美国提供医疗保健劳动力解决方案和人员配备服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021204400097a5d710&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021204400097a5d710&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XLV","AMN","XBI","BK4588","BK4196","BK4581","LABU","BK4585"],"gpt_icon":0},{"id":"2610955288","title":"Humana公布季度虧損擴大，預計2026年盈利將下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2610955288","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610955288?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 22:29","pubTimestamp":1770820140,"startTime":"0","endTime":"0","summary":"Humana公司公布第四季度亏损扩大，原因是医疗成本持续上升，并表示由于其联邦医疗保险计划的质量评级下降，预计 2026 年盈利将大幅下滑。　　该公司报告亏损 10.1 亿美元，合每股亏损 6.61 美元；去年同期亏损 8.62 亿美元，合每股亏损 5.76 美元。　　Humana预计，2026 年个人联邦医疗保险优选计划会员数量将增长约 25%，“这得益于公司以客户为导向的福利策略带来的新增销售与留存率提升，以及客户服务模式的优化”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-11/doc-inhmnhqz7462659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XBI","BK4588","BK4585","XLV","BK4581","LABU"],"gpt_icon":0},{"id":"2610934545","title":"Healthcare Services第四季度EPS為0.44美元 高於預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2610934545","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610934545?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 20:01","pubTimestamp":1770811298,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","LABU","XLV","BK4588","BK4581","XBI","HCAR"],"gpt_icon":0},{"id":"2610933683","title":"和諧健康保險泰安中支被罰16萬，涉編制虛假資料","url":"https://stock-news.laohu8.com/highlight/detail?id=2610933683","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610933683?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 17:54","pubTimestamp":1770803676,"startTime":"0","endTime":"0","summary":"蓝鲸新闻2月11日讯，近日，国家金融监督管理总局泰安监管分局发布了罚单，剑指和谐健康保险股份有限公司泰安中心支公司及其时任经理陈传美。罚单显示，和谐健康保险股份有限公司泰安中心支公司的主要违法违规事实为：编制虚假资料。针对这一行为，国家金融监督管理总局泰安监管分局对其罚款16万元；对时任和谐健康保险股份有限公司泰安中心支公司营业部经理陈传美，警告并处以1.5万元罚款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1770801258420902225","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4585","BK4581","XLV","XBI","BK4588","LABU"],"gpt_icon":0},{"id":"1186140440","title":"醫療保健板塊動態：市場快訊解讀","url":"https://stock-news.laohu8.com/highlight/detail?id=1186140440","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186140440?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 17:23","pubTimestamp":1770801827,"startTime":"0","endTime":"0","summary":"0241 GMT——尽管哈塔勒加集团在第三财季业绩超预期，但其销售增长动能仍显不足，联昌国际证券分析师陈成荣在研究报告中指出。他表示，手套供应过剩局面预计将至少持续至2027年，供需才能重新平衡。陈成荣将哈塔勒加2026至2028财年的核心净利润预测分别上调126%、70%和41%，主要基于成本假设的下调。联昌国际将其目标价从1.18林吉特下调至1.00林吉特，维持持有评级。该股当前上涨2.2%，报0.94林吉特。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","XLV","BK4588","LABU","BK4585"],"gpt_icon":0},{"id":"2610780989","title":"百龍創園(605016.SH)擬設立百龍創園(南京)生物科技有限公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2610780989","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610780989?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 15:40","pubTimestamp":1770795623,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百龙创园(605016.SH)发布公告，公司基于发展战略规划及经营发展需要，以自有资金1000万元，在南京投资设立全资子公司百龙创园(南京)生物科技有限公司(简称“南京百龙”)，公司直接持有南京百龙100%的股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","BK4588","605016","BK4585","BK0226","159837"],"gpt_icon":0},{"id":"2610937278","title":"AMN醫療保健服務公司盤中異動 下午盤股價大漲5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610937278","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610937278?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 02:35","pubTimestamp":1770748555,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日02时35分，AMN医疗保健服务公司股票出现波动，股价大幅拉升5.27%。AMN医疗保健服务公司股票所在的医疗设施行业中，整体涨幅为0.31%。其相关个股中，Park Dental Partners, Inc.、Docgo Inc.、AMN医疗保健服务公司涨幅较大，Newgenivf Group Limited、Agilon Health, Inc.、P3 Health Partners Inc.较为活跃，换手率分别为19.38%、2.69%、2.62%，振幅较大的相关个股有The Oncology Institute Inc C/Wts 、Agilon Health, Inc.、P3 Health Partners Inc.，振幅分别为22.92%、16.71%、15.23%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021102355597a5aed8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021102355597a5aed8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMN","BK4585","BK4196","XLV","BK4581","XBI","BK4588","LABU"],"gpt_icon":0},{"id":"2610663752","title":"資本市場堅定看好「上海藥」！這張「成績單」見證申城創新實力","url":"https://stock-news.laohu8.com/highlight/detail?id=2610663752","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610663752?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 04:02","pubTimestamp":1770667361,"startTime":"0","endTime":"0","summary":"图为上海一家生物医药企业的研发中心内景。新近发布的一张重量级年度榜单，让人在“十四五”收官、“十五五”开局之际，见证了上海生物医药产业的创新实力：2025年，无论是创新药械获批量、产业国际化发展业绩，还是上市企业总体表现，上海都位居国内前列，涌现出一批行业领头羊。特别是按研发管线数排序，全国前十中有八家企业出自上海。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602103645823262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LABU","LU0455707207.USD","BK1589","LU2097828631.EUR","01276","LU0359201612.USD","LU2328871848.SGD","LU2097828714.EUR","LU0359202008.SGD","BK4588","HK0000165453.HKD","LU1023057109.AUD","LU2097828557.USD","BK1191","LU0502904849.HKD","01801","BK1161","LU1969619763.USD","LU2097828805.USD","LU2242644610.SGD","LU2488822045.USD","LU2543165471.USD","LU2097828474.EUR","BK1583","BK4585","LU0359201885.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":186,"code":"91000000","status":"200"}]}}